New Cosmetics In Brief: CICABEL 'Stem Cell' Mask; CYO Beauty; More

  
Generate a summary of this article
Listen to this article
Beta

China-based Grand Fan Group is touting its newly acquired CICABEL mask as a high-tech market disruptor, slated to launch in September. More new cosmetics in brief.

Developed by French "traditional medicine" firm Santinov, the premium CICABEL mask is touted as an innovative addition to the category, featuring ingredients "that can provide energy for skin stem cells, to protect and activate the cells and promote the proliferation of skin epidermal cells," improving facial skin's "self-healing and rejuvenation speed," according to an Aug. 23 release. Chinese firm Grand Fan Group announced its acquisition of the CICABEL brand four days later, noting that the peptide-based facial mask will launch in September. The firm, which distributes three leading hair and body wash and care brands in China, is billing the mask as a "high-tech" disruptor – "one of few beauty products based on biomedical technologies available in the market."

Walgreens Boots Alliance, Inc.'s CYO makeup is "designed to unleash the fun, playful and creative makeup maverick within," according to...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

SpotifyApple PodcastsWebsite

More from Archive

Non-US Approvals - Clone

Devices authorized for marketing outside the US. Data derived from Citeline’s Meddevicetracker. Updated weekly.

Patient access to unapproved medical products allowed under DeFazio, Daschle bills.

 
• By The Tan Sheet

PATIENT ACCESS TO UNAPPROVED MEDICAL PRODUCTS WOULD BE ALLOWED under legislation introduced by Rep. Peter DeFazio (D-Ore.) on July 12 and Sen. Tom Daschle (D-S.D.) on July 14. Called the Access to Medical Treatment Act, the legislation would allow health practitioners to administer unapproved drugs, devices, foods or dietary supplements to patients as long as there is no evidence the treatment causes harm and the patient is informed about the treatment and its possible side effects. DeFazio's bill is identified as HR 2019; Daschle's version will be assigned a bill number the week of July 17.

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Commonly Prescribed Medications for Attention Deficit Hyperactivity Disorder)

 
• By Nabil

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

More from HBW Insight

data

Type:DataArticle | Publication:HBW | Section:Health | Paywall:Premium — Article containing all Composer content for testing (Do not update)

 
• By Nabil, Olga Zviezdicheva, Karen Coleman, José María Rodríguez-López de la Peña y Gutiérrez, Françoise Élodie-Marie d’Artois-Lebœuf, Åsmund Øyvind Størkersen-Løvenskiold, and Nabil

To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.

Test: PDF Link Lifetime

Description description

headline test

description